158 related articles for article (PubMed ID: 28716728)
1. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats.
Qin X; Lu J; Wang P; Xu P; Liu M; Wang X
Biochem Pharmacol; 2017 Nov; 143():129-139. PubMed ID: 28716728
[TBL] [Abstract][Full Text] [Related]
2. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
3. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
4. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
[TBL] [Abstract][Full Text] [Related]
5. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
[TBL] [Abstract][Full Text] [Related]
6. CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research.
Lu J; Shao Y; Qin X; Liu D; Chen A; Li D; Liu M; Wang X
Sci Rep; 2017 Feb; 7():42922. PubMed ID: 28218310
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
Lee JH; Lee A; Oh JH; Lee YJ
Biopharm Drug Dispos; 2012 Nov; 33(8):474-86. PubMed ID: 22936118
[TBL] [Abstract][Full Text] [Related]
8. Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Kim TH; Shin S; Kim S; Bulitta JB; Weon KY; Joo SH; Ma E; Yoo SD; Park GY; Kwon DR; Jeong SW; Lee DY; Shin BS
Molecules; 2017 Sep; 22(9):. PubMed ID: 28891960
[TBL] [Abstract][Full Text] [Related]
9. Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.
Deng S; Wang C; Zhang W; Gao W; Fan A; Zhang Q; Zhang Y; Liu Q; Li N; Liu Q; Zhao J; Li C; Wen X; Zhao D; Chen X
Xenobiotica; 2014 Jul; 44(7):583-90. PubMed ID: 24329500
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.
Yang JZ; Song Y; Xiong JH; Lin YX; Wen C; Li Y; Zhou Y
Biomed Res Int; 2021; 2021():6679082. PubMed ID: 34195278
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K
Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
[TBL] [Abstract][Full Text] [Related]
14. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method.
Rysz MA; Kinzi J; Schäfer AM; In-Albon K; Zürcher S; Schmidlin S; Seibert I; Schwardt O; Ricklin D; Meyer Zu Schwabedissen HE
J Pharm Biomed Anal; 2023 Nov; 236():115716. PubMed ID: 37722165
[TBL] [Abstract][Full Text] [Related]
16. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Mahaffey CM; Davies AM; Lara PN; Pryde B; Holland W; Mack PC; Gumerlock PH; Gandara DR
Clin Lung Cancer; 2007 Nov; 8(9):548-53. PubMed ID: 18186959
[TBL] [Abstract][Full Text] [Related]
18. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
Lee JH; Shin YJ; Kim HJ; Oh JH; Jang YP; Lee YJ
Int J Pharm; 2011 May; 410(1-2):68-74. PubMed ID: 21421030
[TBL] [Abstract][Full Text] [Related]
19. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
[TBL] [Abstract][Full Text] [Related]
20. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
O'Malley M; King AN; Conte M; Ellingrod VL; Ramnath N
J Thorac Oncol; 2014 Jul; 9(7):917-926. PubMed ID: 24926542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
